订阅小程序
旧版功能

738P Quality-adjusted Time Without Symptom or Toxicity (Qa-Twist) and Quality-Adjusted Progression-Free Survival (QA-PFS) of First-Line (1L) Maintenance Niraparib in Patients with Advanced Ovarian Cancer (OC): Results from the PRIMA Trial

M-P. Barretina-Ginesta,B. J. Monk,S. Han,B. Pothuri,A. Auranen,D. Chase,D. Lorusso, C. Anderson,S. Abadie-Lacourtoisie,N. Cloven,E. I. Braicu,A. Amit,A. Redondo, R. Shah, N. Kebede,C. Hawkes,D. Gupta,T. Woodward,D. M. O'Malley,A. J. Gonzalez Martin

Annals of Oncology（2021）

引用 5|浏览39
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要